Received: 09 September 2026
Accepted: 01 October 2026
Published online: 30 October 2026
UDC: 615.37:339.13(574)
DOI: 10.53511/pharmkaz.2026.5.21
Article type: Original Research Article
CURRENT STATE AND DEVELOPMENT PROSPECTS OF THE MARKET FOR IMMUNOBIOLOGICAL PREPARATIONS IN THE REPUBLIC OF KAZAKHSTAN
Bekmukhan D.S.¹*, Abekova A.O.², Amirkhanova A.Sh.¹,
Ustenova G.O.¹, Akhmetsadykov N.N.²
1 Asfendiyarov Kazakh National Medical University, Almaty, 050012, Kazakhstan
2 Antigen Scientific and Production LLP, 4 Azerbayev St., Abay Village, Karasay District, Almaty Region, 040905, Kazakhstan
Corresponding author: Bekmukhan Dana, e-mail: daniebb17@gmail.com
Introduction. The article presents a comprehensive assessment of the immunobiological preparations (IBP) market in the Republic of Kazakhstan, based on data from the State Register of Medicines and Medical Devices of Kazakhstan (as of 17 May 2026, n=97 positions) and compared with the EAEU registration framework (n=153). The scientific novelty consists in applying a risk-oriented approach to interpreting import dependence, accounting for the clinical and logistical significance of ATC segments (V01, J06, J07), and in integrating market economic indicators and SWOT analysis into a unified analytical model.
Materials and methods: continuous sampling from the State Register; data from the “Taldau” IAS of the Bureau of National Statistics (2011–2024); open data of LLP “SK-Pharmacy” on public procurement; unified registration data of the Eurasian Economic Commission. Methods of content analysis, comparative, structural and SWOT analysis, and risk-oriented segment assessment were applied.
Discussion. The data confirm the high dependence on imports in the immunobiological preparations segment in the Republic of Kazakhstan. The share of domestically produced IBP is 5.2%, which is significantly lower than the figure for the pharmaceutical market as a whole. A comparison with the EAEU registration profile revealed the most pronounced structural difference in the V01 allergen segment, whereas the share of J06 was comparable, despite this segment’s complete dependence on imports in Kazakhstan. The results obtained justify the need for a differentiated approach to the development of domestic production and the registration portfolio of immunobiological preparations.
Results. IBPs account for 1.7 % of all registered medicines in Kazakhstan. Vaccines dominate (73.2 %); the share of allergens (4.1 %) significantly lags behind the EAEU figure (41.8 %), evidencing a structural deficit of diagnostic and desensitising agents. Import dependence reaches 94.8 % (5 domestic out of 97). The J06 segment (immunoglobulins and sera) is entirely import-supplied. The share of domestic medicines in the Kazakhstan pharmaceutical market is 15.1 % (2024) and approximately 32 % in public procurement.
Conclusion. The Kazakhstan IBP market is characterised by high structural import dependence and a predominantly preventive orientation. The J06 segment is the most vulnerable. Specific recommendations have been formulated on production localisation, contract manufacturing development, the establishment of a national strategic reserve and the expansion of allergodiagnostic registration.
Keywords: pharmaceutical market, immunobiological preparations, vaccines, immunoglobulins, product range analysis, import dependence, SWOT analysis, EAEU, Republic of Kazakhstan.
количество просмотров / 👁 131